STX 100 - Sentinext Therapeutics
Alternative Names: STX 100/AlhydrogelLatest Information Update: 28 Feb 2021
Price :
$50 *
At a glance
- Originator Sentinext Therapeutics
- Class Enterovirus vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Enterovirus A infections
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for phase-I development in Enterovirus A infections(Prevention) in Australia (Parenteral, Injection)
- 18 Jan 2018 Phase-I clinical trials in Enterovirus A infections (Prevention) in Australia (Parenteral) (ACTRN12617001027303)
- 18 Jul 2017 Enterovirus A vaccine is still in early research for Enterovirus A infection in Malaysia (Parenteral)(ACTRN12617001027303)